Semaglutide and Your Kidneys: Ozempic & Wegovy Guide

Short answer: Semaglutide is the medicine in Ozempic, Wegovy, and the tablet Rybelsus. It needs no dose change if your kidneys are weak, it isn’t cleared by the kidneys, and — unusually for a weight and diabetes drug — it has been proven in a large trial to slow kidney-disease progression in people who have both type 2 diabetes and chronic kidney disease (CKD). The main day-to-day kidney risk is not the drug itself but dehydration from nausea, vomiting, or diarrhea, which can strain the kidneys — especially alongside water pills or blood-pressure medicines.

Written and medically reviewed by Dr. Amir S. Naderi, MD, FASN — board-certified in Internal Medicine and Nephrology (ABIM), trained at UT Southwestern and Johns Hopkins, with a clinical focus on obesity medicine. Last updated: July 8, 2026.

3 things to remember

Semaglutide usually does not need a kidney-dose adjustment.
The main day-to-day kidney risk is dehydration from stomach (GI) side effects.
In type 2 diabetes with CKD, semaglutide has proven kidney protection (the FLOW trial); without diabetes the kidney benefit is likely but less firmly proven.

What semaglutide is, in plain terms

Semaglutide is the active drug inside three products:

Ozempic — a once-a-week injection approved by the FDA to treat type 2 diabetes.
Wegovy — the same drug, at doses approved for weight management (and, separately, to reduce cardiovascular events in adults with obesity and heart disease).
Rybelsus — an oral (tablet) form of semaglutide for type 2 diabetes.

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a natural gut hormone that helps control blood sugar and appetite; an agonist is a drug that switches its receptor on. That single mechanism explains most of what semaglutide does — lower blood sugar, reduce appetite, and produce meaningful weight loss.

If you take Mounjaro or Zepbound instead, those contain tirzepatide, a related but different drug — see our companion guide: Tirzepatide (Mounjaro/Zepbound) and Your Kidneys.

The kidney evidence: this is semaglutide’s real strength

A lot of online writing is vague about “kidney benefits.” Here it is precisely — what is proven, who it applies to, and what is still uncertain.

What is proven (the FLOW trial). In FLOW (published in the New England Journal of Medicine, 2024), adults with type 2 diabetes plus CKD who took semaglutide 1.0 mg had fewer major kidney events — kidney failure, a large (≥50%) drop in kidney function, or death from kidney or cardiovascular causes — than people on placebo. The risk of the main composite outcome was about 24% lower (hazard ratio 0.76). In plain numbers, that was 331 events on semaglutide versus 410 on placebo, over a median of about 3.4 years — roughly one major event avoided for every ~20 people treated (number needed to treat ≈ 20, an approximation calculated from the trial’s published event counts). These are hard endpoints — real outcomes patients care about, not just lab numbers. The trial was stopped early for benefit.

Who that applies to: people with type 2 diabetes and existing CKD. It does not automatically extend to people without diabetes, and it is specific to semaglutide.

The heart evidence (including without diabetes). In the SELECT trial (17,604 adults with obesity and established cardiovascular disease, but without diabetes), major cardiovascular events occurred in 6.5% on semaglutide versus 8.0% on placebo — about a 20% lower risk (hazard ratio 0.80; an absolute difference of roughly 1.5 percentage points). That extended semaglutide’s proven heart benefit beyond diabetes — a genuinely important finding.

What is still less certain (kidneys without diabetes). For people with CKD but no diabetes, the kidney evidence is mostly at the surrogate level — lower urine protein, favorable weight and blood-pressure effects — plus the strong heart data above. A dedicated hard-endpoint kidney trial in non-diabetic CKD is not the basis of today’s proof. So the fair statement is: very likely helpful, but “proven kidney-outcome protection” is strongest in diabetes plus CKD.

Does semaglutide need a dose change if my kidneys are weak?

No. Semaglutide does not require a dose adjustment for reduced kidney function — including in people on dialysis (end-stage kidney disease). That said, real-world experience in dialysis is still limited, use there is off-label, and appetite loss can worsen malnutrition, so it should be managed with your kidney team. It is broken down by the body’s normal protein-recycling process, so it is not cleared by the kidneys and does not build up when kidney function is low.

That is reassuring — but “no dose change” is not the same as “no precautions.” The precautions are about side effects, not drug buildup, and that is the next section.

The real kidney risk with semaglutide: dehydration and “prerenal” injury

Most kidney trouble people run into on semaglutide is not the drug attacking the kidney. It is dehydration.

Semaglutide commonly causes nausea, vomiting, and diarrhea, especially in the first weeks and after each dose increase. If you lose a lot of fluid and don’t replace it, less blood reaches the kidneys. Doctors call this prerenal acute kidney injury (AKI) — “prerenal” meaning the problem is upstream of the kidney (not enough blood flow), and “acute” meaning a sudden, usually reversible drop in function. With prompt fluids, it typically recovers. Regulators noted this pattern early: reports of kidney injury with these drugs have been linked mainly to dehydration from the gastrointestinal side effects, not to a direct toxic effect on the kidney.

The risk rises sharply when that fluid loss lands on top of other medicines that also lower kidney blood flow:

Diuretics (“water pills,” e.g., furosemide, hydrochlorothiazide)
ACE inhibitors or ARBs (blood-pressure/kidney medicines ending in -pril or -sartan)
NSAIDs (over-the-counter pain relievers like ibuprofen or naproxen)
sometimes SGLT2 inhibitors (another diabetes/kidney drug, with its own sick-day rule)

A simple “sick-day plan”

Set this up with your own doctor before you get sick, not during. A common, sensible version:

When to pause: if you can’t keep fluids down for more than a day — repeated vomiting, heavy diarrhea, or clear dehydration (dizziness on standing, very dark urine, urinating much less) — it may be time to temporarily hold certain medicines.
What may be paused (with your doctor’s OK): the diuretic, the ACE inhibitor/ARB, the NSAID, and sometimes an SGLT2 inhibitor, until you’re eating and drinking normally again.
What to do: sip fluids, use oral rehydration if needed, and call your clinic. If you can’t keep water down at all, seek urgent care.
Do not stop any prescribed medicine permanently on your own — see the disclaimer below.

Why your creatinine (and eGFR) can be misleading on semaglutide

Read this twice — it’s one of the most misunderstood points.

Kidney function is usually estimated from a blood test called creatinine, turned into a score called eGFR (a percentage-style estimate of how well the kidneys filter). The catch: creatinine is a waste product of muscle. When you lose weight quickly — and especially if some of that loss is muscle — you make less creatinine, which makes your eGFR look higher, as if your kidneys improved.

Sometimes they genuinely did (losing excess weight can help). Sometimes the number simply moved because you lost muscle, and the kidney itself didn’t change. Relying on creatinine alone can make you think your kidneys are doing better than they are.

What helps: a second marker called cystatin C, which is much less dependent on muscle mass than creatinine (though not perfect, and influenced by other factors). If your weight is dropping fast and your eGFR is bouncing around, ask about a cystatin C check (or a combined creatinine–cystatin C eGFR). Watching your urine protein (albumin-to-creatinine ratio) over time is also very useful — a falling level is one of the most honest signs the kidney is doing better.

(Going deeper: Does losing weight improve eGFR? and Why is my creatinine up on Mounjaro?)

Muscle loss and protein: the quiet issue

Fast weight loss on semaglutide is not all fat — a meaningful share can be muscle, particularly if you don’t eat enough protein or don’t do resistance exercise. For kidney patients this creates a real tension:

Weight-loss medicine reduces appetite, so people eat less protein.
But keeping muscle usually requires enough protein.
Meanwhile, in advanced CKD, doctors sometimes advise limiting protein to ease the kidney’s workload.

There is no single number that fits everyone; the right target depends on your kidney stage, whether you’re on dialysis, and your muscle status — a conversation for a clinician who knows your numbers, ideally a renal dietitian. Two things nearly everyone agrees on: protect muscle where you can, and resistance exercise helps do that during weight loss.

(More: How much protein on a GLP-1 if I have CKD? and Why am I losing muscle on Zepbound?)

Blood pressure — usually a bonus for the kidneys

Semaglutide tends to lower systolic blood pressure modestly — on the order of 4–5 mmHg on average in the weight-management trials (for example, about −5.7 vs −1.6 mmHg over two years in STEP 5). It’s not a blood-pressure medicine, and it works mostly through weight loss, but the direction is downward — and for the kidney, lower pressure means less strain on its filters.

The one caution is over-lowering: if you already take blood-pressure pills or become dehydrated, your pressure can drop too far (dizziness, lightheadedness, fainting). Tell your clinician if that happens — sometimes a blood-pressure medicine is reduced as you lose weight.

(More: Does semaglutide lower blood pressure — and what does that mean for my kidneys?)

What happens if you stop

Semaglutide works by acting on appetite signals; when it leaves your system, appetite usually returns. In the STEP 1 trial extension (Wilding et al., 2022), participants regained on average about two-thirds of the weight they had lost within a year of stopping the drug and lifestyle program. Blood-sugar and blood-pressure improvements can partly fade too, and the kidney-friendly changes (lower urine protein, less hyperfiltration) depend on keeping the weight and metabolic gains. That’s why obesity is increasingly treated as a long-term condition rather than something fixed once. Stopping is not an acute danger to the kidneys, but plan any stop with your doctor.

(More: What happens to my body when I stop Wegovy?)

Compounded semaglutide and your kidneys

“Compounded” semaglutide is a version mixed by a compounding pharmacy rather than made by the manufacturer (Novo Nordisk). During the 2022–2024 shortage it was widely sold, often cheaply through telehealth sites. That situation has changed, and kidney patients in particular should be careful.

Where things stand (U.S., 2026):

The FDA declared the semaglutide shortage resolved on February 21, 2025, which removed the legal basis for mass-compounding.
The FDA then wound down its “enforcement discretion”: smaller (503A) pharmacies could compound semaglutide only until April 22, 2025, and larger (503B) outsourcing facilities only until May 22, 2025.
In 2026, the FDA proposed excluding semaglutide (and tirzepatide and liraglutide) from the list of drugs outsourcing facilities may compound in bulk — moving to close that pathway for good.

Why kidney patients should be extra cautious:

Dosing errors. Many compounded products come in multi-dose vials that require you to draw up your own dose. As of early 2025, the FDA had received more than 455 adverse-event reports tied to compounded semaglutide (a tally the FDA has since updated to 990 as of May 31, 2026) — many from people accidentally taking too much (the FDA has described errors of 5 to 20 times the intended dose), sometimes needing hospitalization. An overdose can trigger severe vomiting and diarrhea → dehydration → acute kidney injury. Careful, slow dose increases matter more when your kidneys are vulnerable.
A specific ingredient concern. The FDA has warned that some compounders used salt forms of semaglutide (such as semaglutide sodium or acetate) that are not the same active ingredient as the FDA-approved drug (Ozempic and Wegovy contain the semaglutide base), with no lawful basis for their use and unknown safety. Unknown ingredients are a special worry for people whose kidneys clear waste less efficiently.
No independent quality control. Compounded products aren’t tested for purity, potency, and sterility the way branded pens are.
Inconsistent strength. Safe, kidney-aware use depends on a known, steady dose you can titrate slowly; batch-to-batch variation makes that harder.

If cost is the reason, talk to your clinician about FDA-approved options first — manufacturer savings programs, and how insurance and prior authorization may cover Ozempic or Wegovy for your situation.

The strongest argument against worrying — and our answer

The steelman: “Semaglutide isn’t cleared by the kidneys, needs no dose change even on dialysis, and — unlike most weight drugs — it has proven hard-endpoint kidney protection in the FLOW trial. Why hedge at all? Isn’t it clearly kidney-protective?”

Our answer: For type 2 diabetes with CKD, the FLOW evidence is genuinely strong, and it’s fair to call semaglutide kidney-protective in that group. The hedging is about reach: FLOW does not prove the same hard-outcome benefit in people without diabetes, and no drug removes risk entirely — proven therapies like blood-pressure control and, where appropriate, SGLT2 inhibitors and finerenone remain part of the plan. Semaglutide adds to that foundation; it doesn’t replace it. Honest precision about who the evidence covers is what makes the strong claim credible.

Questions to bring to your doctor

Given my kidney numbers and diabetes status, is semaglutide the right fit — and how does it sit alongside my other kidney and heart medicines?
Which of my medicines (water pills, blood-pressure pills, NSAIDs, SGLT2 inhibitors) should I hold on sick days?
Should I have a cystatin C check as I lose weight, so we don’t misread my kidney function?
How do we protect my muscle — how much protein, and what kind of exercise?
If cost is an issue, what FDA-approved and insurance/prior-authorization options do I have?

Frequently asked questions

1. Does Ozempic or Wegovy damage the kidneys? No — semaglutide is not considered directly toxic to the kidney (acute kidney injury has been reported, but almost always from dehydration), and it needs no dose change even for weak kidneys. In people with type 2 diabetes and CKD it actually slowed kidney-disease progression (the FLOW trial). The main risk is indirect: dehydration from nausea, vomiting, or diarrhea, more likely if you also take water pills, ACE inhibitors/ARBs, or NSAIDs.

2. Can I take Ozempic with chronic kidney disease? Usually yes. There is no required dose change for reduced kidney function, including dialysis, and the proven kidney benefit is specifically in diabetes plus CKD. Decide and monitor with your clinician. (See: Can I take Ozempic with stage 3 kidney disease? and Can I take Ozempic on dialysis?)

3. Why is my creatinine up on semaglutide? Most often it reflects dehydration from stomach side effects, not the drug harming the kidney, and it usually reverses with fluids. Because creatinine also depends on muscle, rapid weight loss can move the number either way — ask about a cystatin C check. Persistent rises should be checked by your clinician.

4. Does semaglutide protect the heart as well as the kidneys? In the groups studied, yes — kidney benefit in diabetes plus CKD (FLOW) and heart benefit in diabetes and in obesity with heart disease (SELECT). (See: Does Ozempic protect the heart and kidneys?)

5. Do I need to stop semaglutide before surgery? Under 2024 multisociety guidance, most patients can continue their GLP-1 drug before elective surgery using a risk-based approach rather than stopping automatically. People at higher risk of delayed stomach emptying may need extra precautions. Always tell your surgeon and anesthesiologist — the final call is theirs.

6. Is compounded semaglutide safe if I have kidney disease? It carries extra risk — dosing errors, unverified quality, and an FDA salt-form concern — and, as of 2025–2026, broad compounding is no longer a routine legal option in the U.S. Prefer FDA-approved Ozempic or Wegovy and ask about coverage.

References

Show sources

1. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024. (ClinicalTrials.gov NCT03819153.) — Primary composite kidney outcome HR 0.76 (95% CI 0.66–0.88); 331 vs 410 events; median follow-up 3.4 years; stopped early for benefit.
2. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232. — 17,604 participants; MACE 6.5% vs 8.0%; HR 0.80.
3. Wilding JPH, et al. Weight regain after withdrawal of semaglutide (STEP 1 trial extension). Diabetes Obes Metab. 2022. — ~two-thirds of lost weight regained within one year of stopping.
4. STEP 5 and STEP-program analyses. — Systolic blood pressure reductions on the order of ~4–5 mmHg vs placebo.
5. Effect of Renal Impairment on the Pharmacokinetics of Semaglutide. — No clinically relevant PK change across renal impairment/ESRD; no dose adjustment required.
6. Ozempic / Wegovy / Rybelsus U.S. Prescribing Information (accessdata.fda.gov). — Renal impairment: no dose adjustment; monitor renal function with severe GI reactions and volume depletion.
7. FDA. Resolution of Shortage of Semaglutide Injection (Feb 21, 2025), and compounding wind-down (503A to Apr 22, 2025; 503B to May 22, 2025); >455 adverse-event reports; salt-form (semaglutide sodium/acetate) warning.
8. FDA / trade coverage (2026). Proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
9. Multisociety (ASA, AGA, and others). Perioperative management of GLP-1 receptor agonists (2024). — Risk-based approach; most patients may continue.

Educational information only — not medical advice. Never change or stop a prescribed medication without talking to your doctor. This page describes general patterns, not personal recommendations, and does not create a doctor–patient relationship.

Semaglutide (Ozempic and Wegovy) and Your Kidneys